Steven Clemenson, MD
Internal Medicine · Fargo, NDNPI 1174541874
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $238 and has fallen 56.7% since, to $103 in 2021.
Across 30 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$121
- Esperion Therapeutics, Inc.$81
- Merck$69
- Nevro Corp.$41
- Lilly USA, LLC$28
- Sanofi-aventis U.S. LLC$24
- plus $209 from 13 others
What the payments were for
- Food & beverage$572100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 4 | $121 |
| Esperion Therapeutics, Inc. | 1 | $81 |
| Merck | 4 | $69 |
| Nevro Corp. | 1 | $41 |
| Lilly USA, LLC | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| AbbVie | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Abbott | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $13 |
| Antares Pharma, Inc. | 1 | $12 |
| AstraZeneca | 1 | $12 |
How this compares
$572 in reported general payments places this provider in the 75th percentile of 159 internal medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 29 | $33,870 |
| RybelsusSemaglutide | 16 | $26,879 |
| EliquisApixaban | 17 | $21,520 |
| FarxigaDapagliflozin Propanediol | 13 | $17,885 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $5,569 |
| Rosuvastatin Calcium | 59 | $1,361 |
| Tamsulosin Hcl | 71 | $1,240 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $1,236 |
| Omeprazole | 93 | $1,102 |
| Metformin Hcl | 83 | $930 |
| Metoprolol Succinate | 87 | $878 |
| Levothyroxine Sodium | 115 | $876 |
| Atorvastatin Calcium | 124 | $845 |
| Gabapentin | 55 | $828 |
| Lisinopril | 120 | $727 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $16 | $33,87029 claims |
| Novo NordiskRybelsus | $121 | $26,87916 claims |
| AstraZenecaFarxiga | $12 | $17,88513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 159 internal medicine providers in North Dakota.
Other internal medicine in Fargo
- Michael LillestolFargo$18K
- Brent HellaFargo$3K
- Tricia LangloisFargo$2K
- Mark YoheFargo$2K
- Dalton PeasleeFargo$2K
- Anya de LeeuwFargo$1K
- Anastasia SchroederFargo$1K
- Mathew GervingFargo$1K
- Aselo LayawenFargo$1K
- Guillermo EstradaFargo$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.